• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does Viking’s Expanded Shelf and ATM Funding Shift the Bull Case For Viking Therapeutics (VKTX)?

    Simply Wall St·08/04/2026 06:54:18
    语音播报
    • In late July 2026, Viking Therapeutics reported a wider Q2 net loss of US$128.02 million and filed both a universal shelf registration and a US$500 million at-the-market common stock offering, expanding its potential funding options across multiple security types.
    • At the same time, upbeat analyst commentary on obesity drug candidate VK2735’s dosing flexibility and combination potential has drawn attention to how Viking’s capital-raising moves may support the long-term development of its weight-loss and metabolic disorder pipeline.
    • We’ll now examine how the funding flexibility from Viking’s new shelf registration and at-the-market program shapes its investment narrative.

    AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    Viking Therapeutics Investment Narrative Recap

    To own Viking Therapeutics, you need to believe VK2735 can progress successfully through late stage trials and eventually support a commercial franchise in obesity and metabolic disease, despite the company’s ongoing losses and lack of revenue. The new universal shelf and US$500 million at the market program expand funding flexibility, but they do not change the fact that near term sentiment hinges most on upcoming VK2735 clinical readouts, while dilution and cash burn remain key risks.

    Among the recent updates, the widened Q2 2026 net loss of US$128.02 million is most relevant here, because it underlines how dependent Viking is on external capital to fund VK2735’s Phase III VANQUISH trials and the broader pipeline. Higher losses, when paired with fresh equity capacity, sharpen the trade off between progressing catalysts like VK2735 maintenance data and the risk that additional share issuance could pressure existing holders.

    Yet while the funding moves may support VK2735’s progress, investors also need to be aware that...

    Read the full narrative on Viking Therapeutics (it's free!)

    Viking Therapeutics’ narrative projects $118.5 million in revenue and $12.9 million in earnings by 2029. This implies revenue growing from zero today to $118.5 million and an earnings increase of about $372.5 million from -$359.6 million today.

    Uncover how Viking Therapeutics' forecasts yield a $92.72 fair value, a 184% upside to its current price.

    Exploring Other Perspectives

    VKTX 1-Year Stock Price Chart
    VKTX 1-Year Stock Price Chart

    Before this news, the most optimistic analysts were treating VK2735 as a potential US$497.5 million revenue story by 2029, so if you lean toward that view you are effectively assuming the new financing tools help accelerate that path, while others may see the same offerings as amplifying dilution and execution risk.

    Explore 10 other fair value estimates on Viking Therapeutics - why the stock might be worth less than half the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Viking Therapeutics research is our analysis highlighting 3 important warning signs that could impact your investment decision.
    • Our free Viking Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viking Therapeutics' overall financial health at a glance.

    Looking For Alternative Opportunities?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.